Gemplus

Gemphire Therapeutics was a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia and non-alcoholic steatohepatitis (NASH). The company's lead product candidate, gemcabene, is a first-in-class, once-daily, oral small molecule designed to lower levels of LDL-C, high-sensitivity C-reactive protein (hsCRP), and triglycerides. Gemcabene works through a dual mechanism of action by inhibiting cholesterol synthesis and enhancing the clearance of triglyceride-rich lipoproteins. In 2019, Gemphire entered into a definitive merger agreement with NeuroBo Pharmaceuticals, transitioning its focus toward NeuroBo's neurodegenerative and cardiometabolic pipeline.